TL;DR
A number of lead candidates with strong EGFR inhibitory potential, promising pharmacokinetic profiles, and mutant selectivity were successfully identified by the integrated computational approach.
Combined computational and preliminary cell-based findings support compound 4i as a promising lead for further investigation of EGFR-targeted anticancer activity and biochemical EGFR kinase inhibition and target-engagement studies are required to determine the mechanism of action.
A molecular modeling study integrating molecular dynamics and free energy calculation was conducted to comprehend the distinct binding manner of Lazertinib binding to EGFR and the structural need for the inhibitory activity, and confirms that Lazertinib preferentially binds to EGFRT790M with the same conformation as in...
Findings establish coumarin-derived scaffolds as promising starting points for the development of next-generation CDK4-targeted therapeutics and provide a strong computational foundation for future experimental validation in NSCLC.
Next-generation EGFR inhibitors with a particular focus on allosteric inhibitors developed for L858R-mutant NSCLC are surveyed, offering the possibility of double-drugging the mutant receptor to achieve deeper and more durable responses for EGFR L858R+ patients.
The overall results of the MD showed the overall stability of the NEK2–ligand complexes, and thus these three compounds are promising NEK2 inhibitor candidates and could be further validated in vitro and in vivo for clinical application.
Docking predicted stronger binding to wild-type EGFR and reduced affinity for the T790M mutant, whereas co-binding produced compound-dependent improvements, and an integrated framework provides structural, dynamic, and energetic criteria for prioritize cooperative allosteric-orthosteric co-binding chemotypes for experi...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
